STOCKHOLM, March 22, 2017 – Laurent Leksell acquires 730,769 new shares of class A, representing a value of SEK 71.2 M. This is done through conversion of his entire outstanding 2012/2017 convertible loan of class A in Elekta. In connection with the conversion, Laurent Leksell has today also sold a total of 250,000 shares of class B in the company.
Laurent Leksell will, after completion of the conversion, directly and indirectly control shares corresponding to 30.6 percent of the total number of votes in Elekta.
In 2012, the Swedish Securities Council (Aktiemarknadsnämnden, statement 2012:22) granted Laurent Leksell an exemption from the mandatory bid obligation that could arise in connection with Laurent Leksell’s conversion of convertibles to shares in the company. Hence, the conversion will not result in any mandatory bid obligation for Laurent Leksell, even though he will control more than 30 percent of the total number of votes in Elekta after the completion of conversion.
# # #
This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 21:00 CET on 22 March, 2017.
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com.